Long a Dream, It's Now Real: A Fast and Accurate TB Test that Doesn't Need Phlegm

Why It Matters

The MiniDock MTB can dramatically expand access to reliable TB diagnostics in low‑resource settings, accelerating treatment initiation and reducing transmission, which is critical for meeting global TB elimination goals.

Key Takeaways

• MiniDock MTB costs $300, test fee $3‑4 per use
• Uses tongue swab or phlegm, eliminating need for sputum
• Meets WHO accuracy targets in 1,400‑patient multi‑country study
• Portable device enables TB testing in remote clinics
• Cannot detect early‑stage or drug‑resistant TB yet

Pulse Analysis

Tuberculosis remains the world’s deadliest infectious disease, killing over a million people each year. Conventional sputum microscopy, unchanged since the 1800s, suffers from low sensitivity and requires patients to produce phlegm—a challenge for children, the elderly and the severely ill. These hurdles cause diagnostic delays, multiple clinic visits, and continued transmission. The COVID‑19 pandemic accelerated swab‑based molecular diagnostics, creating a pathway for innovative TB tests that are faster, cheaper, and more patient‑friendly.

Pluslife’s MiniDock MTB, launched last year, combines a simple tongue swab or sputum sample with rapid DNA amplification and machine‑vision analysis. The handheld unit costs about $300, and each assay runs $3‑4, dramatically undercutting microscope costs. In a NEJM‑published trial of nearly 1,400 symptomatic patients across seven African and Asian nations, the device achieved sensitivity and specificity that meet WHO’s minimum thresholds, whether using swabs or sputum. The WHO formally recommended the test shortly after the study, paving the way for broader adoption.

The test’s portability and low price promise to expand TB screening to peripheral health posts, schools, and mobile clinics, shortening the diagnostic cascade and enabling earlier treatment initiation. While it cannot yet identify drug‑resistant strains or very early infection with low bacterial loads, its high accuracy for active TB can reduce unnecessary antibiotics and curb transmission. Continued refinement and integration with resistance‑detecting assays could eventually deliver a single point‑of‑care solution, accelerating global efforts to meet the WHO’s End TB targets by 2035.